{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=INCB024360&page=2", "query": { "intervention": "INCB024360", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=INCB024360&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-19T10:09:01.327Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03358472", "title": "Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Epacadostat", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 89, "start_date": "2017-12-01", "completion_date": "2025-10-30", "has_results": true, "last_update_posted_date": "2025-12-03", "last_synced_at": "2026-09-19T10:09:01.327Z", "location_count": 14, "location_summary": "Anaheim, California • Sacramento, California • Santa Rosa, California + 11 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03358472" }, { "nct_id": "NCT03217669", "title": "Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Non-small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "Epacadostat", "type": "DRUG" }, { "name": "sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Chao Huang", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2018-02-22", "completion_date": "2025-08-01", "has_results": false, "last_update_posted_date": "2023-05-03", "last_synced_at": "2026-09-19T10:09:01.327Z", "location_count": 2, "location_summary": "Fairway, Kansas • Westwood, Kansas", "locations": [ { "city": "Fairway", "state": "Kansas" }, { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03217669" }, { "nct_id": "NCT03291054", "title": "Epacadostat and Pembrolizumab in Patients With GIST", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastrointestinal Stromal Tumors" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Epacadostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2018-02-28", "completion_date": "2020-08-19", "has_results": true, "last_update_posted_date": "2024-06-11", "last_synced_at": "2026-09-19T10:09:01.327Z", "location_count": 2, "location_summary": "Ann Arbor, Michigan • New York, New York", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03291054" }, { "nct_id": "NCT03374488", "title": "Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "UC (Urothelial Cancer)" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Epacadostat", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 84, "start_date": "2017-12-22", "completion_date": "2020-07-23", "has_results": true, "last_update_posted_date": "2025-08-22", "last_synced_at": "2026-09-19T10:09:01.327Z", "location_count": 24, "location_summary": "Chandler, Arizona • Orange, California • San Francisco, California + 19 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03374488" }, { "nct_id": "NCT02118285", "title": "Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer", "Fallopian Tube Carcinoma", "Primary Peritoneal Carcinoma" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "NK cells", "type": "BIOLOGICAL" }, { "name": "IL-2", "type": "BIOLOGICAL" }, { "name": "INCB024360", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 2, "start_date": "2014-07-28", "completion_date": "2015-11-12", "has_results": false, "last_update_posted_date": "2017-12-05", "last_synced_at": "2026-09-19T10:09:01.327Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02118285" }, { "nct_id": "NCT03348904", "title": "Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Epacadostat", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2017-12-27", "completion_date": "2018-05-22", "has_results": true, "last_update_posted_date": "2019-06-13", "last_synced_at": "2026-09-19T10:09:01.327Z", "location_count": 2, "location_summary": "Anaheim, California • Wichita, Kansas", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Wichita", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03348904" }, { "nct_id": "NCT02178722", "title": "Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Microsatellite-instability (MSI) High Colorectal Cancer (CRC)", "Endometrial Cancer", "Head and Neck Cancer", "Hepatocellular Carcinoma (HCC)", "Gastric Cancer", "Lung Cancer", "Lymphoma", "Renal Cell Carcinoma (RCC)", "Ovarian Cancer", "Solid Tumors", "UC (Urothelial Cancer)", "Melanoma", "Bladder Cancer", "Triple Negative Breast Cancer (TNBC)" ], "interventions": [ { "name": "MK-3475", "type": "DRUG" }, { "name": "INCB024360", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 444, "start_date": "2014-07-17", "completion_date": "2020-11-06", "has_results": true, "last_update_posted_date": "2022-02-14", "last_synced_at": "2026-09-19T10:09:01.327Z", "location_count": 24, "location_summary": "La Jolla, California • Los Angeles, California • Sacramento, California + 19 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Farmington", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02178722" }, { "nct_id": "NCT03532295", "title": "Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioma", "Glioblastoma" ], "interventions": [ { "name": "Epacadostat", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Radiation therapy", "type": "RADIATION" }, { "name": "Retifanlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2020-04-20", "completion_date": "2025-10-31", "has_results": true, "last_update_posted_date": "2025-11-21", "last_synced_at": "2026-09-19T10:09:01.327Z", "location_count": 4, "location_summary": "Phoenix, Arizona • Rochester, Minnesota • St Louis, Missouri + 1 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03532295" }, { "nct_id": "NCT02298153", "title": "A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "NSCLC (Non-small Cell Lung Carcinoma)", "UC (Urothelial Cancer)" ], "interventions": [ { "name": "Epacadostat", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2015-01-27", "completion_date": "2017-11-08", "has_results": false, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-09-19T10:09:01.327Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • New Haven, Connecticut • Boston, Massachusetts + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02298153" }, { "nct_id": "NCT03006302", "title": "Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Epacadostat", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "CRS-207", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "GVAX Pancreas Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2018-01-31", "completion_date": "2024-08-05", "has_results": true, "last_update_posted_date": "2024-10-08", "last_synced_at": "2026-09-19T10:09:01.327Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03006302" } ] }